AI assistant
PFIZER INC — Director's Dealing 2026
Feb 27, 2026
29831_dirs_2026-02-27_9abb7bd8-f460-4d0f-ae75-5ccd07e89f53.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2026-02-25
Reporting Person: Fonseca Lidia (Executive Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-02-25 | Common Stock | M | 56888.0000 | $33.8200 | Acquired | 101579.0000 | Direct |
| 2026-02-25 | Common Stock | F | 1058.0000 | $27.0900 | Disposed | 100521.0000 | Direct |
| 2026-02-25 | Common Stock | F | 54066.0000 | $26.9200 | Disposed | 46455.0000 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-02-25 | Stock Appreciation Rights | $33.8200 | M | 56888.0000 | Disposed | 2026-02-25 | Common Stock (56888.0000) | Direct |
Footnotes
F1: The reported transaction constitutes the earn-out of stock appreciation rights (including dividend equivalents thereon).
F2: The reported transaction constitutes the withholding of shares to satisfy tax obligations in connection with earn-out of stock appreciation rights.
F3: The reported transaction constitutes the withholding of shares to cover payment of exercise price in connection with earn-out of stock appreciation rights (including dividend equivalents thereon).
F4: Under the terms of the settlement of the stock appreciation rights the 20-day average of the closing prices of Pfizer common stock ending on the settlement date is used.